Vasopressors and Shock Management
Those who are experiencing a decrease in their blood pressure might be advised to take vasopressors. These drugs are used to increase the rate of blood circulation in the body. The agents are also used in treating conditions that can cause low blood pressure.
During shock, the cardiovascular system fails to provide adequate tissue perfusion. This results in reduced oxygen delivery to cells, which impairs cellular function. This causes organ dysfunction, and in some cases multiorgan failure. The goal of shock management is to restore perfusion pressures to normal.
Shock can be classified as hemodynamic, cardiogenic, or distributive. Typically, treatment of shock occurs concurrently with diagnosis and evaluation. Vasopressors are used to control hypotension in hemodynamic shock. However, they can also worsen hemorrhage. In obstructive shock, inotropes are a viable alternative.
Various studies have examined the clinical outcomes of patients treated with vasopressors. These studies have shown that the use of vasopressors is associated with increased mortality. This increase is time-dependent. It increases by about 5.3% for every hour of delay in the initiation of a vasopressor. The resulting decrease in cardiac output increases the risk of developing sustained hypotension.
Classical vasodilatory shock management involves escalating vasopressors stepwise. This approach leads to excessive catecholamine exposure and prolonged hypoperfusion. The goal is to prevent prolonged hypotension by using a physiologic-guided approach.
In this study, patients who received concomitant VP and NE were evaluated in a retrospective cohort study. The primary outcome was the incidence of hypotension within 24 hours of discontinuation of the first vasopressor. Other clinical outcomes included 28-day mortality, length of hospital stay, and ICU readmission. The data were gathered from electronic medical records. The distribution of baseline data was compared using Fisher exact tests. A two-sided p-value was considered statistically significant.
Subgroup analyses were conducted by a type of shock. Septic shock was the largest subgroup. The VP1 group did not have a difference in hypotension, but the NE1 group had a significantly higher incidence of hypotension. The VP1 group had a shock reversal rate of 78.5 percent by day 15. The NE1 group had a shocking reversal at a significantly earlier time than the VP1 group.
Whether the order of vasopressor discontinuation is important for patients with septic shock is unclear. However, it is possible that medical necessity may have influenced the order.
A systematic review of previous research has found that the order of vasopressor discontinuation has an effect on the length of the shock. The longer the time the patient remains on a vasopressor, the higher the risk of dying. The order of discontinuation should be determined by the bedside practitioner.
During septic shock, vasopressors are used to correct hypotension. These medications increase arterial blood pressure and maintain MAP, thereby increasing tissue perfusion. They may also be used to correct absolute and relative hypovolemia. These are a staple of many protocols.
The Surviving Sepsis Campaign recommends the use of norepinephrine as the first-line vasopressor for septic shock. However, there are recent studies recommending other approaches to the use of vasopressors. A systematic review of 32 randomized controlled trials comparing noradrenaline, dopamine, and adrenaline with no vasopressors was carried out.
These studies revealed that noradrenaline significantly decreased adverse events and mortality rates. Interestingly, noradrenaline is more effective than dopamine in septic shock.
In addition, noradrenaline should be used as the first-line vasopressor in adults with septic shock. Its use has been shown to reduce mortality rates by two-thirds. In the CENSER trial, early initiation of norepinephrine led to improved shock control. This study suggests that early NE infusions may help to redistribute the blood from the unstressed volume to the stressed volume and improve cardiac preload and the efficacy of resuscitation.
The CENSER trial also investigated the effects of early norepinephrine administration on ventricular arrhythmias and cardiac output. It found that early initiation of vasopressors reduced new-onset arrhythmias and cardiogenic pulmonary edema. It also suggested that early initiation of vasopressors decreased 28-day mortality rates.
The CENSER study enrolled 100 adult patients with septic shock in a medical ICU. The study subjects were compared for their baseline patient characteristics and duration of IV vasopressor use. The data was analyzed using descriptive statistics.
The authors concluded that septic shock is a serious and difficult condition to manage in the emergency department. Its management requires a multidisciplinary approach, including fluid resuscitation and antibiotics. Septic shock is the leading cause of morbidity and mortality in intensive care units, and it continues to affect approximately one in ten patients admitted to an ICU. It is therefore important to consider the role of vasopressors in the treatment of septic shock.
The Surviving Sepsis Guidelines recommend the use of norepinephrine and vasopressin as adjunctive therapy in septic shock. The use of angiotensin II may be appropriate for patients who are refractory to vasopressors or who have a low cardiac output.
Managing Distributive Shock is a common clinical condition. It is defined as a lack of adequate intravascular volume. This causes significant hypotension. It carries high morbidity and mortality. The management of this shock is a multidisciplinary team effort. During treatment, nurses monitor the hemodynamic stability of the patient.
The main goals of fluid resuscitation are to achieve adequate tissue perfusion and to stabilize blood pressure. An ideal PAOP is 15 to 18 mm Hg. During treatment, supplemental oxygen is provided through a face mask.
For patients with a normal or above-normal circulating volume, inotropic support is the most appropriate. In this setting, positive inotropes are used to promote heart contractility. These agents include dopamine, norepinephrine, and phenylephrine.
In these patients, venous adrenergic stimulation is the key to maintaining adequate tissue perfusion. When venous adrenergic agonists are administered, blood shifts from the venous pool to the circulation. The effect is similar to that of a centrally administered vasopressor. The use of these agents is controversial.
Although these therapies improve end-organ perfusion, they can lead to the worsening of hemorrhage. This is especially true in hemorrhagic shock. In addition, the inflammatory mediators released by white blood cells can cause additional cytokines that activate nuclear factor kappa B. This activation triggers nitric oxide production. These mediators may also increase vasodilation.
For patients with decreased cardiac output, vasopressors can improve the outcome of the disease. In this scenario, it is important to continue the treatment for a longer period of time.
In addition, septic shock is more proinflammatory than other forms of shock. This is because the host’s response to infection is impaired. When a person becomes ill, inflammatory mediators are released by white blood cells. These mediators bind to cell surface receptors and activate the immune system. The resulting IgE molecules attach to mast cells in the tissues. They then release histamine.
In a patient with a septic shock, the onset of the symptoms is typically accompanied by fever and chills. The skin may be warm or moist and the earlobes may be clammy. These symptoms are often mistaken for heart failure.
Several classes of drugs, including phosphodiesterase inhibitors, are used as vasopressors. They are potent vasodilators that decrease preload and reduce afterload, which promotes smooth muscle relaxation. They also indirectly increase intracellular levels of cAMP and cGMP. These molecules regulate various physiological processes and the primary effects of neurotransmitters.
Inhibitors of phosphodiesterase enzymes are commonly used in the treatment of chronic obstructive pulmonary disease and asthma. In addition to vasodilation, these drugs can also help to inhibit airway inflammation. Some of the first phosphodiesterase inhibitors to be discovered were methylxanthines. These compounds are also commonly used for the short-term treatment of pulmonary diseases, such as bronchodilation.
Inotropes are a class of agents that have peripheral vasoconstriction effects and cardiac contractility enhancement. The evidence base is limited. However, many patients would not survive without inotropic support.
Inotropes are considered to be useful in the management of heart failure and AMI. In the case of heart failure, they are given with a goal of augmenting cardiac output. They have also been shown to have a variety of central nervous system and metabolic effects.
Phosphodiesterase type 3 inhibitors (PDE3 inhibitors) have been used in the management of coronary heart disease and erectile dysfunction. They can cause a range of adverse effects, including flushing, headache, nausea, diarrhea, and dyspepsia. They are also associated with ventricular arrhythmias.
Phosphodiesterase type 4 inhibitors (PDE4 inhibitors) are also used to treat psoriasis, asthma, and chronic obstructive pulmonary disease. These drugs inhibit phosphodiesterase isoenzyme IV, which is the main phosphodiesterase enzyme involved in the breakdown of cAMP and cGMP. They are also known to reduce SVR.
The most important effect of vasopressors is the elevation of mean arterial pressure (MAP) in the bloodstream. Achieving a MAP of 65 mmHg is necessary to maintain adequate perfusion of the vital organs. Infusions of vasopressors are often subcutaneously injected in critically ill patients. They can also be administered by IV.
The use of inotropes has become a common practice in cardiogenic shock, particularly in the setting of AMI. However, the net effect of these agents is not always anticipated by the treating physician. Consequently, dosages must be adjusted to account for changes in the patient’s clinical condition.
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
U.S. National Library of Medicine. (n.d.). https://www.ncbi.nlm.nih.gov/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Health A-Z. (2022, April 26). Verywell Health. https://www.verywellhealth.com/health-a-z-4014770
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/